Ipratropiumbromid Hexal (Ipratropium Bromide)

Ipratropium bromide works by competitively blocking muscarinic receptors (M1, M2, M3) on airway smooth‑muscle cells. This inhibition prevents acetylcholine‑mediated contraction, leading to relaxation of bronchial smooth muscle and bronchodilation. The inhaled route delivers the drug directly to the lungs, limiting systemic exposure.

The dose of ipratropium bromide is individualized by the prescribing healthcare professional based on the patient’s condition, severity, and response. Typical regimens involve multiple inhalations per day using a nebulizer or metered‑dose inhaler, but the exact amount and frequency must be determined by a qualified prescriber.

Safety data for ipratropium bromide in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details, and any necessary import documentation.

The primary alternative class is short‑acting beta‑agonists such as albuterol. While beta‑agonists stimulate bronchodilation via adrenergic receptors, ipratropium bromide achieves bronchodilation by blocking muscarinic receptors. Ipratropium is often used in combination with beta‑agonists for additive effect, especially in patients who need anticholinergic therapy or have suboptimal response to beta‑agonists alone.

The product should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed when not in use and avoid exposing the solution to extreme temperatures. Follow any additional handling instructions provided on the label.

Ipratropiumbromid Hexal is administered by inhalation. The medication can be delivered via a nebulizer solution or a metered‑dose inhaler, depending on the formulation supplied. Patients should follow the inhalation technique recommended by their healthcare professional to ensure optimal deposition in the lungs.

Serious risks include paradoxical bronchospasm, which can worsen breathing, and severe allergic reactions such as anaphylaxis or angioedema. Other important concerns are urinary retention, especially in patients with prostate enlargement, and increased intraocular pressure in individuals with narrow‑angle glaucoma. Prompt medical attention is required if any of these events occur.

Patients with a known hypersensitivity to ipratropium bromide or any component of the formulation should avoid the product. It is also contraindicated in individuals with narrow‑angle glaucoma, significant urinary retention, or bladder outlet obstruction, as anticholinergic effects may exacerbate these conditions.